TBPH Stock Analysis: Buy, Sell, or Hold?
TBPH - Theravance Biopharma, Inc.
$16.67
-0.09 (-0.54%)
▼
5d:
+0.6%
30d:
+9.24%
90d:
-12.4%
BUY
MODERATE Confidence
Analysis Updated: Apr 28, 2026 12:00 AM ET
Earnings: May 14, 2026
14d
Get Alerted When TBPH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: TBPH shows positive signals but monitor for confirmation. Market pricing in 3.2% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: TBPH shows positive signals but monitor for confirmation. Market pricing in 3.2% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$1.39
Based on -32.6% avg growth
INTRINSIC VALUE TODAY
$0.86
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TBPH is currently trading at $16.67, which is considered slightly high relative to its 30-day fair value range of $15.54 to $16.86. The stock's valuation (Forward PE: 12.4) is in line with its historical norms (11.3). At these levels, the market is pricing in 3.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, TBPH is in a strong downtrend. Immediate support is located at $16.14, while resistance sits at $17.24.
Market Sentiment: TBPH has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TBPH is in a strong downtrend. Immediate support is located at $16.14, while resistance sits at $17.24.
Market Sentiment: TBPH has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$15.54 -
$16.86
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
72.4%
All Signals
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($17.20)
- NEUTRAL: Market pricing in 3.2% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$15.54 -
$16.86
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$16.14
Resistance Level
$17.24
Current Trend
Strong Downtrend
Technical data as of
Apr 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
12.37
Wall Street Target
$17.20
(+2.6%)
Revenue Growth (YoY)
144.7%
Profit Margin
98.5%
Valuation Premium vs History
+3.2% premium
PE vs Historical
12.4 vs 11.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+3.2%
(market-implied from PE analysis)
1-Year Target
$17.30
(+3%)
2-Year Target
$17.85
(+7%)
3-Year Target
$18.42
(+10%)
3-Yr Target (if PE normalizes)
(PE: 12→11)
PE COMPRESSION
$16.83
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.6, Growth: -69.2%)
$20.36
(+22%)
Base:
(SPY PE: 12.4, Growth: -69.2%)
$12.22
(-27%)
Bear:
(PE: 10.5, Growth: -69.2%)
$10.39
(-38%)
📈
Valuation based on Current Earnings
Trailing PE: 8.16 | Current EPS (TTM): $2.06
Bull Case
$12.16
(-27%)
Analyst growth -34.2%, PE expands to 9.0
Base Case
$11.06
(-34%)
Market implied -34.2%, PE stable at 8.2
Bear Case
$11.43
(-32%)
Severe decline -20.0%, PE contracts to 6.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: April 29, 2026 10:53 AM ET
Data refreshes hourly during market hours. Next update: 11:53 AM
Data refreshes hourly during market hours. Next update: 11:53 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TBPH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Rhonda Farnum
SELL
31067 shares
2026-03-16
Rhonda Farnum
SELL
31067 shares
2025-12-03
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 59 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$548 | 59 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$878 | 58 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 56 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 55 HOLD |
